Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPAS pharmacokinetic study of once-daily inhaled tobramycin in cystic fibrosis
NL-OMON27081Unknown
- Sponsor
- Erasmus MC, Rotterdam
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tobramycin in cystic fibrosis (CF) and Pseudomonal infection (2 arms), sponsored by Erasmus MC, Rotterdam. Primary endpoint: Systemic bioavailability of inhaled tobramycin. Status: unknown.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonal infection
Beyond the preview
Go deeper on NL-OMON27081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27081.